Related Experiment Video
Updated: Nov 18, 2025
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Renal cell cancer
Thomas E Hutson1, Robert A Figlin
1Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, and US Oncology Research Network, Dallas, Texas, USA.
Abstract:
Metastatic renal cell cancer has traditionally been treated with interferon and interleukin-2. An improved understanding of the biology of renal cancer has engendered novel targeted therapeutic agents that have altered the natural history of this disease. The vascular endothelial growth factor and its related receptor and the mammalian target of rapamycin signal transduction pathway in particular have been utilized as therapeutic targets. Sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab/interferon alfa have improved clinical outcomes in randomized trials. Other antiangiogenic agents have also demonstrated activity in early studies. Given the availability of multiple treatment options, several questions emerge as to how to integrate these new therapies into the management of metastatic renal cell cancer. Recently reported and planned clinical trials will help clarify the role of these agents. The future of therapy for renal cancer appears promising owing to the efficacy of these novel agents.
Insights
Novel targeted therapies, including antiangiogenic agents and mTOR inhibitors, are improving outcomes for metastatic renal cell cancer. Clinical trials are guiding the integration of these advanced treatments for better patient management.
Area of Science:
- Oncology
- Medical Science
Background:
- Metastatic renal cell cancer (mRCC) treatment historically relied on interferon and interleukin-2.
- Advances in understanding renal cancer biology have led to novel targeted therapies.
- Key pathways targeted include vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR).
Purpose of the Study:
- To review the efficacy of novel targeted agents in metastatic renal cell cancer.
- To discuss the integration of new therapies into mRCC management.
- To highlight the promising future of renal cancer treatment.
Main Methods:
- Review of randomized clinical trials and early studies on targeted agents for mRCC.
- Analysis of agents targeting VEGF and mTOR pathways.
- Discussion of clinical trial data for sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab/interferon alfa.
Main Results:
- Sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab/interferon alfa have demonstrated improved clinical outcomes in randomized trials.
- Other antiangiogenic agents have shown activity in preliminary studies.
- These novel therapies represent a significant advancement over traditional treatments.
Conclusions:
- Novel targeted therapies have significantly altered the natural history of metastatic renal cell cancer.
- Ongoing and planned clinical trials are crucial for defining optimal treatment strategies.
- The efficacy of these agents offers a promising outlook for future renal cancer therapy.
More Related Videos
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:10Nephrons
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...